GlaxoSmithKline Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Bonus
• Share holding
• Capital structures
• Ratio

Sep ' 24	Sep ' 23	Sep ' 22	Mar ' 22	Sep ' 21

Sales

1,811.05

1,691.40

1,635.07

1,599.90

1,764.99

Operating profit

548.37

427.83

404.85

370.08

425.08

Interest

0.64

0.71

1.07

0.85

1.14

Gross profit

615.77

492.39

453.73

398.67

470.72

EPS (Rs)

25.40

20.43

18.43

80.72

19.07

Other income

68.04

65.27

49.95

29.44

46.78

Stock adjustment

9.36

-34.67

-116.86

7.88

4.25

Raw material

270.58

225.18

255.53

240.13

312.25

Power and fuel

-

-

-

-

-

Employee expenses

301.99

310.21

293.16

282.43

327.80

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

680.75

762.85

798.39

699.38

695.61

Provisions made

-

-

-

-

-

Depreciation

33.27

34.47

32.18

33.22

35.31

Taxation

156.85

129.10

112.36

295.34

112.36

Net profit / loss

430.34

346.12

312.24

1,367.47

323.05

Extra ordinary item

4.69

17.30

3.05

1,297.36

-

Prior year adjustments

-

-

-

-

-

Equity capital

169.41

169.41

169.41

169.41

169.41

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

30.28

25.29

24.76

23.13

24.08

GPM (%)

32.77

28.03

26.93

24.47

25.98

NPM (%)

22.90

19.70

18.53

83.93

17.83